Ozempic’s maker is in trouble. Tablets may be the answer
Just a few years ago, Novo Nordisk was the darling of the healthcare industry. Now it is teetering.
We haven't written up this one. The Age has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.